Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Robo4 counteracts VEGF signaling

Nature Medicine volume 14, pages 372–373 (2008)Cite this article

Robo4 expression in emerging blood vessels can neutralize signaling through the angiogenic factor vascular endothelial growth factor (VEGF) and maintain vessel integrity. The findings could lead to new therapeutic targets for angiogenesis and vascular leakage (pages 448–453).

In recent years, it has emerged that guidance cues responsible for neuronal development also have crucial roles in vessel formation and maturity. Many researchers have drawn a comparison between an actively developing axonal sprout and a newly forming blood vessel, as both migrate, elongate or retract in response to cues from surrounding tissues and matrix. Families of axonal guidance molecules influencing vessel development include semaphorins, ephrins and Slit proteins1. In particular, the role of Slit proteins in angiogenesis—inducing the sprouting of new vessels from existing ones—has been uddied by conflicting reports implicating them as both pro- and antiangiogenic molecules2.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: The work of Jones et al.3

Kim Caesar

References

  1. Eichmann, A., Makinen, T. & Alitalo, K. Genes Dev. 19, 1013–1021 (2005).

    Article  CAS  Google Scholar 

  2. Legg, J.A., Herbert, J.M., Clissold, P. & Bicknell, R. Angiogenesis published online, doi:10.1007/s10456-008-9100-x (9 February 2008).

    Google Scholar 

  3. Jones, C.A. et al. Nat. Med 14, 448–453 (2008).

    Article  CAS  Google Scholar 

  4. Weis, S.M. & Cheresh, D.A. Nature 437, 497–504 (2005).

    Article  CAS  Google Scholar 

  5. Casanovas, O., Hicklin, D.J., Bergers, G. & Hanahan, D. Cancer Cell 8, 299–309 (2005).

    Article  CAS  Google Scholar 

  6. Wang, B. et al. Cancer Cell 4, 19–29 (2003).

    Article  Google Scholar 

  7. Park, K.W. et al. Dev. Biol. 261, 251–267 (2003).

    Article  CAS  Google Scholar 

  8. Suchting, S., Heal, P., Tahtis, K., Stewart, L.M. & Bicknell, R. FASEB J. 19, 121–123 (2005).

    Article  CAS  Google Scholar 

  9. Bedell, V.M. et al. Proc. Natl. Acad. Sci. USA 102, 6373–6378 (2005).

    Article  CAS  Google Scholar 

  10. Sabatier, C. et al. Cell 117, 157–169 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sara M. Weis and David A. Cheresh are in the Department of Pathology and the Moores University of California–San Diego Cancer Center, Lisette M. Acevedo, University of California, San Diego, La Jolla, California 92093-0803, USA. dcheresh@ucsd.edu,

    Lisette M Acevedo, Sara M Weis & David A Cheresh

Authors
  1. Lisette M Acevedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara M Weis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A Cheresh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Acevedo, L., Weis, S. & Cheresh, D. Robo4 counteracts VEGF signaling. Nat Med 14, 372–373 (2008). https://doi.org/10.1038/nm0408-372

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0408-372

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing